RxDoctor Payments Data

Glenn Yates, MD

Internal Medicine · Montgomery, ALNPI 1124019781

Payments from drug & device makers

$889in general payments, 2019–2025

Across 54 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$194
  • Novo Nordisk$163
  • Amgen$96
  • GSK$80
  • Pfizer$56
  • Abbott$55
  • plus $245 from 12 others

What the payments were for

  • Food & beverage$889100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$889 in reported general payments places this provider in the 60th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$125,451
Medicare patients
281
Services billed
3,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$153,515
MounjaroTirzepatide98$121,521
EliquisApixaban150$120,677
JardianceEmpagliflozin118$119,204
TrulicityDulaglutide72$88,235
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$47,629
JanuviaSitagliptin Phosphate31$37,375
FarxigaDapagliflozin Propanediol38$35,708
MyrbetriqMirabegron30$21,715
Breo ElliptaFluticasone/Vilanterol33$18,801
GemtesaVibegron17$11,856
Rosuvastatin Calcium347$10,921
Atorvastatin Calcium675$10,157
MultaqDronedarone Hcl12$9,051
Tresiba Flextouch U-100Insulin Degludec11$7,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$28$209,756170 claims
Novo NordiskOzempic$163$153,515127 claims
PfizerEliquis$56$120,677150 claims
Boehringer IngelheimJardiance$18$119,204118 claims
GSKTrelegy Ellipta, Breo Ellipta$80$66,42979 claims
AstraZenecaFarxiga, Symbicort$194$39,46054 claims
MerckJanuvia$12$37,37531 claims
Sanofi-aventis U.S. LLCMultaq$18$9,05112 claims
AbbVieSynthroid$31$3,92235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →